IN8bio Overview
Latest PEG ratio for IN8bio: 3.32 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow3.32
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
IN8bio posts a PEG ratio of 3.32. That is below the Healthcare sector average of 11.64. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a PEG ratio near 11.64 is typical. IN8bio's 3.32 is lower that level. That is roughly 71.5% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
IN8bio's PEG ratio of 3.32 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.
Context for INAB's PEG ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.64), and (3) consistency with growth and profitability. This page covers the first two; IN8bio's other metric pages and overview cover the third.
Judging IN8bio against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in PEG ratio easier to interpret. Start with 3.32 here, then scan peer and history charts to see if the gap is persistent.
